Biolase Technology, Inc. (BLTI) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-10.94M
Depreciation and amortization	776K
Loss on disposal of assets, net
Impairment of property, plant and equipment
Provision for bad debts
Provision for inventory excess and obsolescence
Amortization of discounts on term loan payable
Amortization of debt issuance costs
Stock-based compensation	2.47M
Other equity instruments compensation
Other non-cash compensation
Deferred income taxes	45K
Accounts receivable	-863K
Inventory	-1.36M
Prepaid expenses and other assets	688K
Customer deposits	-7K
Accounts payable and accrued liabilities	2.12M
Deferred revenue	-202K
Net cash and cash equivalents used in operating activities
Additions to property, plant and equipment	-1.06M
Net cash and cash equivalents used in investing activities
Proceeds from term loan payable
Payments under term loan payable
Payment of debt issuance costs
Proceeds from equity offering, net of expenses	9.54M
Proceeds from exercise of stock options	1K
Net cash and cash equivalents provided by financing activities
Effect of exchange rate changes	60K
Increase (decrease) in cash and cash equivalents	951K
Cash and cash equivalents, beginning of year	11.7M
Cash and cash equivalents, end of period	12.65M
Interest	3K
Income taxes	66K

Entities mentioned with BLTI

View All Entities